Prostaglandin F2α-F-prostanoid receptor regulates CXCL8 expression in endometrial adenocarcinoma cells via the calcium–calcineurin–NFAT pathway  by Sales, Kurt J. et al.
Biochimica et Biophysica Acta 1793 (2009) 1917–1928
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbamcrProstaglandin F2α-F-prostanoid receptor regulates CXCL8 expression in endometrial
adenocarcinoma cells via the calcium–calcineurin–NFAT pathway
Kurt J. Sales a, David Maldonado-Pérez a,b, Vivien Grant a, Rob D. Catalano a, Martin R. Wilson a,
Pamela Brown a, Alistair R.W. Williams c, Richard A. Anderson b, E. Aubrey Thompson d, Henry N. Jabbour a,⁎
a MRC Human Reproductive Sciences Unit, The Queen's Medical Research Institute, 47 Little France Crescent, The University of Edinburgh, Edinburgh, EH16 4TJ, UK
b Reproductive and Developmental Sciences, The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, EH16 4TJ, UK
c Pathology, The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, EH16 4TJ, UK
d Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida 32224, USA⁎ Corresponding author. Tel.: +44 131 2426220; fax:
E-mail address: h.jabbour@hrsu.mrc.ac.uk (H.N. Jabb
0167-4889 © 2009 Elsevier B.V.
doi:10.1016/j.bbamcr.2009.09.018
Open access under CC BYa b s t r a c ta r t i c l e i n f oArticle history:
Received 22 August 2009
Accepted 30 September 2009
Available online 9 October 2009
Keywords:
PGF2α
FP receptor
Chemokine
Calcineurin
Prostaglandin
CXCL8Pro-inﬂammatory mediators, like prostaglandin (PG) and chemokines, promote tumourigenesis by
enhancing cell proliferation, migration of immune cells and recruitment of blood vessels. Recently we
showed elevated expression of the chemokine (C-X-C motif) receptor 2 (CXCR2) in endometrial
adenocarcinomas localized to neutrophils and neoplastic epithelial and vascular cells. Furthermore we
found that PGF2α-F-prostanoid (FP) receptor regulates the expression of the CXCR2 ligand CXCL1, to promote
neutrophil chemotaxis in endometrial adenocarcinomas. In the present study we identiﬁed another CXCR2
ligand, CXCL8 as a target for PGF2α-FP receptor signalling which enhances epithelial cell proliferation in
endometrial adenocarcinoma cells in vitro and in nude mice in vivo. We found that PGF2α-FP receptor
interaction induces CXCL8 expression in endometrial adenocarcinoma cells via the protein kinase C–
calcium–calcineurin–NFAT signaling pathway. Promoter analysis revealed that CXCL8 transcriptional
activation by PGF2α signaling is mediated by cooperative interactions between the AP1 and NFAT binding
sites. Furthermore, PGF2α via the FP receptor induced the expression of the regulator of calcineurin 1 isoform
4 (RCAN1-4) via the calcineurin/NFAT pathway in a reciprocal manner to CXCL8. Using an adenovirus to
overexpress RCAN1-4, we found that RCAN1-4 is a negative regulator of CXCL8 expression in endometrial
adenocarcinoma cells. Taken together our data have elucidated the molecular and cellular mechanism
whereby PGF2α regulates CXCL8 expression via the FP receptor in endometrial adenocarcinomas and have
highlighted RCAN1-4 as a negative regulator of CXCL8 expression which may be exploited therapeutically to
inhibit CXCL8-mediated tumour development.
© 2009 Elsevier B.V. Open access under CC BY license.1. Introduction
The human endometrium undergoes a state of inﬂammation and
repair in a cyclical nature every 28 days [1]. This is characterized by
the induction of inﬂammatory enzymes such as cyclooxygenase-2
(COX-2), release of prostaglandins (PG) and cytokines [2]. Chronic
inﬂammation has been linked to increased cancer risk, for example
hepatitis and colitis have been shown to promote liver [2,3] and
colon cancer [2,4] respectively. By contrast, non-steroidal anti-
inﬂammatory drug use and suppression of the COX-prostaglandin
axis is associated with an inverse risk of developing cancer. In the
Western world, endometrial cancer is one of the leading gyneco-
logical malignancies [5–7]. We and others have demonstrated
elevated expression of the inﬂammatory enzyme COX-2, prosta-
glandin receptors and elevated signaling of the pro-inﬂammatory
prostaglandins PGE2 and PGF2α and growth factors such as vascular+44 131 2426231.
our).
 license.endothelial growth factor and ﬁbroblast growth factor in endome-
trial adenocarcinomas [8–13]. These ﬁndings suggest that endome-
trial cancers are controlled in an autocrine/paracrine manner by
the COX-PG axis via the synthesis and release of potent growth
factors.
Dysregulated chemoattractive cytokine (chemokine) expression is
known to contribute to pathologies by promoting uncontrolled
proliferation, invasion and migration of cells [14]. For example the
chemokine C-X-C motif ligand 1 (CXCL1) and its G protein-coupled
receptor CXCR2 has been demonstrated in regulating growth and
development of colon carcinomas via the COX-PGE2 signaling axis
[15]. Furthermore we have recently shown that CXCL1 expression is
elevated in endometrial adenocarcinomas and promotes neutrophil
chemotaxis via PGF2α-FP receptor signaling to extracellular signal-
regulated kinase [16]. Another chemokine ligand of the CXCR2
receptor, CXCL8, has also been implicated in tumourigenesis by
enhancing melanoma cell proliferation [17], alveolar epithelial
neoplasia [18] and breast cancer development [19], however its
expression and role in endometrial adenocarcinoma is unclear.
1918 K.J. Sales et al. / Biochimica et Biophysica Acta 1793 (2009) 1917–1928Here we identiﬁed CXCL8 as a target for PGF2α-FP receptor
signaling in endometrial adenocarcinoma cells. Using an in vitro
model system, endometrial adenocarcinoma explants and a nude
mouse xenograft model, we elucidated the molecular mechanisms
mediating PGF2α-FP receptor signaling to CXCL8 in endometrial
adenocarcinoma cells its potential role in endometrial tumourigenesis.
2. Materials and methods
2.1. Reagents
YM-254890 was kindly donated by Astellas Pharma Inc (Tsukuba,
Japan). NFκB SN-50 inhibitory peptide was purchased from Biomol
(Exeter, UK). Cyclosporin A and Inhibitor of NFAT-Calcineurin
Association-6 (Inca-6), U73122, 4-cyano-3-methylisoquinoline
(4C3MQ), SB225002 and RO-318220 were purchased from Calbio-
chem (Nottingham, UK). PGF2α, AL8810, transretinoic acid and EGTA
were purchased from Sigma (Dorset, UK). The TAM-67 (dn cJun) was
a kind gift from Dr Michael Birrer (National Cancer Institute,
Maryland, USA) as described [20]. The CXCL8 constructs [21,22]
were a kind gift from Dr Allan Brasier (Department of Internal
Medicine, University of Texas Medical Branch, Galveston, Texas).
2.2. Cell line, culture and treatments
Wild type Ishikawa cells and Ishikawa cells engineered to stably
express the full length human FP (PTGFR, accession no: NM_000959)
receptor to the levels observed in endometrial adenocarcinomas,
referred to as Ishikawa FPS cells, were cultured as described
previously [10]. Ishikawa FPS cells were manufactured commercially,
clonally selected and veriﬁed as described in our previous study [10].
Using this in vitro model system, we have previously demonstrated
that the PGF2α-FP receptor signalling in Ishikawa FPS cells parallels
the ex vivo effects of PGF2α on endometrial adenocarcinoma explants
[9,10]. Transient transfections were performed using Superfect
(Qiagen, Crawley, UK) as per the manufacturer's protocol. The
concentrations of all chemical inhibitors and antibodies were
determined empirically by titration using the manufacturer's guide-
lines as described in our previous studies [23]. A list of all chemical
inhibitors and their targets is outlined in Table 1. Cell viability was
determined for each inhibitor using the CellTitre 96 AQueous One
Solution assay (Promega, Southampton, UK) as described [24,25]. Cells
were treated with 100 nM PGF2α alone or in the presence of AL8810,
YM254890, U73122 , 43CMQ, RO-318220, Cyclosporine A, Inca-6,
EGTA, SN-50 for the time indicated. In parallel cells treated withTable 1
List of reagents summarising the targets of each compound.
Compound Concentration Tar
AL8810 50 μM FP
YM254890 1 μM Gq
U73122 10 μM PLC
4C3MQ 1 μM Pro
RO-318220 1 μM Pro
Inca-6 40 μM Inh
sub
blo
the
CsA 1 μM Inh
NF
pho
SN-50 100 μg/ml Pep
Trans-retinoic acid (RA) 1 μM Inh
me
Ethylene glycol tetraacetic
acid (EGTA)
1.5 mM Che
tha
SB225002 30 nM Selvehicle (either distilled water, ethanol or dimethyl sulfoxide v/v) and
chemical inhibitor served as a control for each treatment. Fold increase
was calculated by dividing the values obtained from the PGF2α/PGF2α
-inhibitor treatments by the vehicle/vehicle-inhibitor treatments. All
in vitro cell culture experiments were carried out in duplicate.
2.3. Patients and tissue collection
Endometrial adenocarcinoma tissue (N=30; 10 of each poorly,
moderately and well differentiated adenocarcinoma) and normal
endometrial tissue (N=30; 10 of each proliferative, early secretory
and mid secretory endometrium) were obtained from women
undergoing hysterectomy as detailed in our prior studies [10,24].
Ethical approval was obtained from Lothian Research Ethics Commit-
tee and written informed consent was obtained from all subjects
before tissue collection.
2.4. Cytokine array
The human cytokine antibody array I (RayBiotech, Inc., Norcross,
GA) was used according to the manufacturer's instructions using
conditioned medium collected from cultured Ishikawa FPS cells
treated with vehicle or 100 nM PGF2α for 24 h [9]. The membranes
were exposed to X-ray ﬁlm and proteins quantiﬁed by densitometric
analysis using the ImageQuant TL software (GE Healthcare, Little
Chalfont, UK).
2.5. Immunohistochemistry
Immunohistochemistry was performed on endometrial adenocar-
cinoma tissues or nude mouse xenografts (N=20) [8,9,24] using the
Vision Biosystems Bond Immunostaining Robot under normal
operating conditions (Leica Microsystems Wetzlar, Germany). Immu-
nostaining was performed following antigen retrieval using speciﬁc
primary antibodies CXCL8 (1:200) or mouse monoclonal BrdU
antibody (1:1000) or cytokeratin 18 antibody (1:500). Control tissue
was incubated with immunoglobulin (IgG) from the host species
(data not shown).
2.6. Taqman quantitative RT-PCR
Quantitative RT-PCR was performed as detailed before [24] using
sequence-speciﬁc primers and probes. Data were analyzed and
processed using Sequence Detector v1.6.3 (Applied Biosystems).
Expression of analyzed genes was normalised to RNA loading forget Reference
receptor antagonist [42]
/11 inhibitor [43,44]
beta inhibitor [45]
tein kinase A inhibitor [46]
tein kinase C inhibitor [47]
ibitor of interaction between calcineurin and its
strate nuclear factor of activated T cells (NFAT);
cks at the substrate recognition site but not at
catalytic site. Inhibits NFAT dephosphorylation.
[48]
ibits the dephosphorylation and translocation of
AT to the nucleus by inhibiting calcineurin
sphatase activity
[49]
tide inhibitor of NF-kB translocation to the nucleus [50]
ibits AP1 complex formation (cJun homodi
risation or cJun/cFos heterodimerisation)
[51]
lating agent with higher afﬁnity for calcium
n magnesium
[52]
ective non-peptide inhibitor of CXCR2, inhibiting [53]
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standard. Results are expressed as fold increase above vehicle treated
cells. Data are presented as mean±SEM.
2.7. Secreted CXCL8 quantiﬁcation
Secreted CXCL8 was quantiﬁed using an in-house enzyme linked
immunosorbent assay (ELISA) described previously [26]. A matched
pair of capture and biotinylated labeled detection antibodies for
CXCL8 and recombinant CXCL8were used (R&D Systems, Oxford, UK).
Data are presented as mean±SEM from at least 3 independent
experiments.
2.8. Luciferase reporter assay
pNFκB-Luc and pAP1-Luc vectors were purchased from Clontech
(Mountain View, CA). RCAN1-4 promoter reporter plasmids and
pNFAT-Luc were kindly donated by Dr Takashi Minami (University of
Tokyo, Tokyo, Japan) [27]. The CXCL8 promoter reporter constructs
used have been previously described [22]. Cell transfection, stimula-
tion and luciferase reporter assay was performed as described
previously using the dual luciferase assay kit (Promega, Southampton,
UK) [10,23]. Experiments were normalised for cell number and
transfection efﬁciency by co-transfecting Ishikawa FPS cells with the
appropriate ﬁreﬂy luciferase reporter together with the renilla
luciferase reporter gene. Data are presented as mean±SEM from at
least 3 independent experiments.
2.9. Immunoblot analysis
Western blot analysis on FPS cells was carried out as described
previously [25]. After resolving and immunoblotting, membranes
were incubated overnight at 4°C, with a rabbit anti RCAN-1-4 antibody
(1:5000), a kind gift from Dr ErikW. Bush (Myogen, Inc, Westminster,
CO), together with a mouse anti β-actin antibody (1:800) (Santa Cruz
Biotechnology, Santa Cruz, CA). The following day, cells were washed
and incubated with goat anti-rabbit Alexaﬂuor 680 (1:5000; Invitro-
gen) and goat anti-mouse IRDye™ 800 (1:5000; Rockland, Gilbersville,
PA) for 60 min at room temperature. Blots were visualized using an
Odyssey infrared imaging system (LI-COR, Cambridge, UK).
2.10. RCAN adenovirus infection
Ishikawa FPS cellswere plated in 6well plates at a density of 200,000
cells/well. After 24h incubation, cellswerewashedwith PBS and1mlof
fresh medium containing 5 adenovirus molecules of infection (MOI or
pfu)/plated) per cell was added to each well [25]. Cells were incubated
for another 24 h and serum starved overnight before treatment with
vehicle or 100 nM PGF2α. Adenovirus containing a scrambled sequence
(CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTC TTCATCTTG
TTG TTTTT) was used as a control. Data are presented as mean±SEM
from at least 3 independent experiments.
2.11. Lentivirus shRNA gene silencing
A short hairpin RNA (shRNA) lentivirus [25] was used to knock
down the expression of RCAN1. Brieﬂy, Ishikawa FPS cells were plated
in 12 well plates at a density of 80,000 cells/well with either RCAN1
ShRNA lentivirus or lentivirus containing a scrambled sequence
(CCGGCAAC AAGAT GAAGAGCA CCAAC TCGAGTTGG TGCTC
TTCATCTTG TTG TTTTT). After 24 h incubation, cells were infected
with virus-containing media at a 1:10 dilution of virus to target cell
media and 0.6 μg/ml Polybrene to give an infection rate of 1 virus per
cell (1 molecule of infection; MOI). The day after, medium was
replaced with fresh serum-containing medium and 48 h post-
infection, the cells which were serum starved overnight, were treatedwith vehicle or 1 nM PGF2α. Data are presented as mean±SEM from 3
independent experiments.
2.12. Proliferation assay
Proliferation of Ishikawa FPS cells was determined using a CellTitre
96®AQueous One Solution cell proliferation assay (Promega) as per
the manufacturer's protocol as detailed previously [24]. Cells were
treated with serum-free medium containing 5 μg/ml CXCL8 in the
presence or absence of the CXCR2 antagonist SB225002 for 24, 48 or
72 h. Control wells received the same concentration of vehicle alone
or vehicle and inhibitor. Following treatment, proliferation was
measured by addition of the CellTitre 96®AQueous One Solution
reagent as per the manufacturer's protocol. Data are presented as
mean±SEM from 3 independent experiments.
2.13. Xenograft tumour growth
A suspension of 5×106 Wild type Ishikawa or Ishikawa FPS cells in
a total volume of 0.2 ml DMEMwas injected subcutaneously into each
dorsal ﬂank of CD1-Foxn1nu mice (Charles River, UK). The mice
(n=30) were divided into two groups of equal tumour size after
engraftment (1 week). The mice were injected twice weekly with
100 μg IgG or CXCL8 neutralising antibody (R&D systems, Abingdon,
UK) via intra-peritoneal injection for 4 weeks. At the end of the study
animals were injected with 50 mg/kg BrdU 2 h prior to culling. A
proportion of the tumour was ﬁxed in 0.2% paraformaldehyde for
wax-embedding and immunohistochemistry. The animals were
maintained under sterile conditions in individually vented cages. All
animal care and experimental protocols were approved by the animal
ethics committee of the University of Edinburgh and the Home Ofﬁce
of the United Kingdom government.
2.14. BrdU/cytokeratin staining and quantiﬁcation
The expression of BrdU and cytokeratin in Ishikawa FPS IgG control
and FPS CXCL8-neutralised tumours was determined by standard
immunohistochemistry techniques as described above and quantiﬁed
using standard stereology techniques. Brieﬂy images were captured
using a ×40 plan apo objective from a BH2 microscope (Olympus,
Tokyo, Japan) ﬁtted with an automatic stage (Prior Scientiﬁc
Instruments Ltd., Cambridge, UK) using a video camera (HV-C20;
Hitachi, Tokyo, Japan) and were analyzed with Image-Pro Plus 4.5.1
software with a Stereology 5.0 plug-in (Media Cybernetics, Woking-
ham, Berkshire, UK). A total of 100 randomised ﬁelds of view were
examined and counted from 8 tumours in each group. The total
number of BrdU/cytokeratin positive epithelial cells per ﬁeld of view
were counted and expressed as a percentage of the total points per
ﬁeld of view and presented as mean±SEM.
2.15. Statistical analysis
The data in this study was analyzed by T-test or ANOVA using
Prism 4.0c (Graph Pad, San Diego, CA).
3. Results
3.1. PGF2α-FP receptor activation induces CXCL8 expression and release
in Ishikawa FPS cells
Using a chemokine protein array, we identiﬁed the inﬂammatory
chemokine CXCL8 as a target for PGF2α-FP receptor signaling in
endometrial adenocarcinoma cells (Fig. 1A). We subsequently investi-
gated the regulation of CXCL8 via the F-prostanoid receptor in
endometrial adenocarcinoma cells and the potential role of CXCL8 in
endometrial adenocarcinomas. PGF2α stimulation of Ishikawa FPS cells
Fig. 1. CXCL8 is induced by PGF2α-FP receptor signalling. (A) Chemokine release in response to 100 nM PGF2α treatment in Ishikawa FPS cells. Conditioned medium obtained from
Ishikawa FPS cells treated with vehicle or 100 nM PGF2α for 24 h was tested for the expression of chemokines using the human cytokine antibody array (RayBiotech). (B) FPS cells
were transiently transfected with the full length −1400/+44 CXCL8 promoter and treated with vehicle or 100 nM PGF2α for 4, 6, 8 and 24 h. CXCL8 promoter activity was
determined by luciferase reporter assay. (C) CXCL8mRNA expression in Ishikawa FPS cells following treatment of cells for 2, 4, 6, 8, 12, 24, 48 and 72 hwith 100 nM PGF2α. (D) CXCL8
protein secretion in Ishikawa FPS cells following treatment of cells for 2, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h with 100 nM PGF2α. (b is signiﬁcantly different from a; Pb0.01). Data are
represented as mean±SEM.
1920 K.J. Sales et al. / Biochimica et Biophysica Acta 1793 (2009) 1917–1928[10] resulted in a signiﬁcant time-dependent increase in the expression
of CXCL8 promoter (Fig. 1B; Pb0.001), mRNA (Fig. 1C; Pb0.001) and
protein (Fig. 1D; Pb0.001). Co-treatment of Ishikawa FPS cells with
100nMPGF2α andAL8810, YM254890,U73122,RO-318220, EGTA, Inca-
6 or CsA, but not 4C3MQ signiﬁcantly inhibited the expression of CXCL8
mRNA(Fig. 2A; Pb0.05) and release of CXCL8protein (Fig. 2B; Pb0.001).
3.2. PGF2α induces activation of CXCL8 promoter through AP1 and NFAT
To determine the regions of the CXCL8 promoter involved in
regulating gene transcription in response to PGF2α-FP receptor
interaction, Ishikawa FPS cells were transiently transfected with
plasmid cDNA containing the full length (−1400/+44) or serial
deletions of the CXCL8 promoter (−162/+44, −132/+44, −99/
+44 and −54/+44) linked to the luciferase reporter gene [21,22].
We found a considerable reduction in promoter activity when the
CXCL8 promoter was truncated down to −99 nucleotides of the 5′
ﬂanking region of the CXCL8 gene (Fig. 2C; Pb0.01). No further
reduction in promoter activity was observed in the −54 nucleotides
truncated construct which only contains the CXCL8 TATA box (Fig. 2C;
Pb0.01). The use of site directed mutated versions of the−162 CXCL8
promoter-luciferase construct at consensus binding sequences for
activator protein 1 (AP1) and nuclear factor of activated T-cells
(NFAT) showed that these binding sites are required for the induction
of transcription of CXCL8 by PGF2α (Fig. 2C, Pb0.01). Furthermore, we
conﬁrmed that CXCL8 transcriptional activation in response to PGF2α-
FP receptor signalling occurred via the PKC–calcium–calcineurin–
NFAT pathway (Fig. 2D, Pb0.01) and this was independent of nuclear
factor (NF)κB (as NFAT and NFκB have similar consensusmotifs on the
DNA binding domain) since the NFκB inhibitory peptide SN-50
(100 μg/ml) did not reduce the activity of CXCL8 promoter induced by
PGF2α (Fig. 2D, Pb0.01). In agreement with this, Ishikawa FPS cells
transfected with the pNFκB-Luc vector and treated with 100 nMPGF2α did not induce NFκB-driven luciferase activity, whereas
transfection of Ishikawa FPS cells with the pNFAT-Luc or pAP1-Luc
vector which contains the a cis-acting NFAT or AP1 enhancer element
showed a time dependent increase in luciferase activity in response to
treatment with 100 nM PGF2α (Fig. 2E, Pb0.01). We conﬁrmed that
the PGF2α-mediated activation of the −162/+44 CXCL8 reporter
gene construct occurred via the NFAT and AP1, but not NFκB, elements
using speciﬁc inhibitors of NFAT (Inca-6) and AP1 (transretinoic acid;
RA) and NFκB (SN-50) (Fig. 2F, Pb0.01).
3.3. NFAT and AP1 cis-enhancer elements are co-regulated by PGF2α
NFAT complexes with the two AP1 subunits, cJun and cFos via
direct protein-protein interactions to co-ordinate promoter activity
[28–30]. Treatment of Ishikawa FPS cells with 100 nM PGF2α and
AL8810, YM254890, U73122, RO-318220, EGTA, Inca-6 or CsA, but not
4C3MQ signiﬁcantly inhibited the activation of pNFAT-Luc (Fig. 3A;
Pb0.01) and pAP1-Luc (Fig. 3B; Pb0.01) luciferase. Since these
transcriptional regulatory proteins are both regulated by PGF2α via
the PKC–calcium–calcineurin–NFAT pathways and are essential for
CXCL8 activity, we performed further studies to determine whether
the CXCL8 promoter was co-operatively regulated by the NFAT-AP1
complex as has been described for other cytokines such as IL-2 [31].
We found that transretinoic acid (which causes dissociation of the
AP1 complex) or co-transfection of Ishikawa FPS cells with the dn c-
Jun (also called TAM67) that lacks the transactivating domain [20]
abolished both the transcriptional activity of AP1 (Fig. 3C, Pb0.01)
and NFAT (Fig. 3D; Pb0.01) promoter elements. Furthermore,
disruption of the AP1 protein complex with the dn c-Jun construct
abolished the transcriptional activity of the truncated −162/+44 as
well as the full length−1400/+44 (Fig. 3E; Pb0.01) CXCL8 promoter
activity in response to PGF2α treatment indicating that an AP1-NFAT
protein complex is essential for CXCL8 activation.
Fig. 2. PGF2α-FP receptor-mediated CXCL8 is regulated via the calcium–calcineurin–NFAT pathway. (A) CXCL8 mRNA expression and (B) protein secretion in Ishikawa FPS cells
treated for 8 h with vehicle, 100 nM PGF2α, 100 nM PGF2α in the absence/presence of AL8810 (50 μM), YM254890 (1 μM), U73122 (10 μM), 4C3MQ (1 μM), RO-318220 (1 μM ), EGTA
(1.5 mM), Inca-6 (40 μM) or CsA (1 μM) as determined by quantitative RT-PCR analysis and ELISA respectively. (C) CXCL8 luciferase activity in Ishikawa FPS cells transiently
transfected with the full length (−1400/+44) or sequential 5′ deletions (−162/+44, −132/+44, −66/+44, −54/+44) of the CXCL8 promoter or the −162/+44 construct
containing site-directed mutations in the NFAT or AP1 binding sites. Cells were treated with vehicle or 100 nM PGF2α for 8 h and expressed as fold above the−54/+44 construct
which contains only the TATA box. (D) FPS cells were transiently transfected with the full length−1400/+44 CXCL8 promoter and treated with vehicle or 100 nM PGF2α for 8 h in
the absence/presence of AL8810, YM254890, EGTA, CsA, Inca-6 or SN-50. CXCL8 promoter activity was determined by luciferase reporter assay. (E) FPS cells were transiently
transfected with pAP1-luc, pNFAT-luc or pNF NFκB -luc reporter cDNA constructs and treated for 2, 4, 8 or 24 hwith vehicle or 100 nM PGF2α. (F) CXCL8 luciferase activity in FPS cells
transfected with the−162/+44 CXCL8 luciferase reporter plasmid. Cells were treated with vehicle or 100 nM PGF2α for 8 h in absence/presence of Inca-6, SN-50 or transretinoic
acid (RA). (b is signiﬁcantly different from a; Pb0.05). Data are represented as mean±SEM.
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calcineurin negative modulator RCAN1
Having identiﬁed that the PGF2α-FP receptor activation of CXCL8
was mediated via the calcineurin–NFAT signalling pathway, we
explored whether CXCL8 was regulated by the regulator of calci-
neurin 1 (RCAN1), previously known as Down syndrome criticalregion gene 1 (DSCR1) or Adapt 78 which is known to endogenously
modulate calcineurin–NFAT signaling [32]. We identiﬁed that PGF2α
induces the expression of isoform 4 of RCAN1 (Fig. 4A) in rapid time-
dependent manner, with maximal levels of expression after 4 h
(Fig. 4B; Pb0.001). Co-treatment of Ishikawa FPS cells with AL8810,
YM254890. U73122, RO-318220, EGTA, Inca-6 or CsA, but not 4C3MQ
signiﬁcantly inhibited the expression of RCAN1-4 mRNA (Fig. 4C;
Fig. 3. The AP1 protein c-Jun activates the AP1 and NFAT cis-acting enhancer elements to transactivate the CXCL8 promoter. FPS cells were transiently transfected with pNFAT-luc (A)
or pAP1-luc (B) and treated for 8 h with vehicle, 100 nM PGF2α, 100 nM PGF2α in the absence/presence of AL8810, YM254890, U73122, 4C3MQ, RO-318220, EGTA, Inca-6 or CsA and
NFAT cis-acting enhancer DNA activation was measured by luciferase reporter assay. Ishikawa FPS cells were transiently transfected with the pAP1-luc (C) or pNFAT-luc (D) reporter
plasmid and either incubated with transretinoic acid or co-transfected with an empty vector or dn c-Jun cDNA construct. Ishikawa FPS cells were transfected with the−162/+44 or
−1400/+44 (E) CXCL8 luciferase reporter cDNA and co-transfected with empty vector or dn c-Jun cDNA. Cells were treated with vehicle or 100 nM PGF2α for 8 h. (b is signiﬁcantly
different from a and c is signiﬁcantly different from a and b; Pb0.01). Data are represented as mean±SEM.
1922 K.J. Sales et al. / Biochimica et Biophysica Acta 1793 (2009) 1917–1928Pb0.001). These data indicate that PGF2α-FP receptor signalling
regulates RCAN1-4 expression in a reciprocal time dependent manner
to CXCL8 via the same calcium–calcineurin–NFAT signal transduction
pathway regulating CXCL8.
3.5. RCAN1-4 overexpression inhibits PGF2α-induced expression of CXCL8
RCAN1-4 is known to bind to calcineurin and inhibit activation of
NFAT when overexpressed [33]. Overexpression of RCAN1-4 in
Ishikawa FPS cells (Fig. 4D, E and F; Pb0.01) using RCAN1-4
adenovirus signiﬁcantly reduced the PGF2α-FP receptor induction ofCXCL8 promoter and mRNA expression and protein secretion
compared to cells infected with the scrambled control virus.
Conversely, infection of cells with RCAN1-4 lentivirus short hairpin
(Sh) RNA which ablates RCAN1-4 protein expression (Fig. 5A),
augmented the PGF2α-FP receptor activation of CXCL8 mRNA
(Fig. 5B; Pb0.01) and protein (Fig. 5C; Pb0.01) conﬁrming that
RCAN1-4 is a negative regulator of CXCL8.
We further investigated the effect of disruption of NFAT activity
by RCAN1-4 overexpression on activation of the NFAT and AP1 DNA
transactivation domains. We found that as observed for the
disruption of the AP1 transcription complex with the transretinoic
Fig. 4. RCAN1-4 overexpression negatively regulates CXCL8 in Ishikawa FPS cells. (A) FPS cells were treated with vehicle or 100 nM PGF2α for 8 h. The various RCAN isoforms (RCAN1-
1, 1-2, 1-4) were detected by PCR using speciﬁc primers and normalised to expression of GAPDH. (B) RCAN1-4 mRNA expression in Ishikawa FPS cells as measured by real-time
quantitative RT-PCR analysis following treatment of cells for 0, 2, 4, 6, 8, 12, 24, 48 and 72 hwith 100 nM PGF2α. (C) FPS cells treated for 8 hwith vehicle, 100 nM PGF2α, 100 nM PGF2α
in the absence/presence of AL8810, YM254890, U73122, 4C3MQ, RO-318220, EGTA, Inca-6 or CsA and RCAN1-4 expression was determined by quantitative RT-PCR analysis.
Ishikawa FPS cells were transiently transfected with the full length −1400/+44 CXCL8 promoter (D) or left untransfected (E and F) and infected with either scrambled control
adenovirus or RCAN1-4 adenovirus for 24 h. Cells were then treated with vehicle or 100 nM PGF2α for 8 h and CXCL8 promoter (D), mRNA (E) and protein (F) expression was
determined by luciferase reporter assay, quantitative RT-PCR analysis or ELISA respectively (b is signiﬁcantly different from a and c is signiﬁcantly different from a and b; Pb0.01).
Data are represented as mean±SEM.
1923K.J. Sales et al. / Biochimica et Biophysica Acta 1793 (2009) 1917–1928acid or dn c-Jun (Fig. 3C), inhibiting NFAT activity with the RCAN1-4
adenovirus also inhibited the AP1 and NFAT (Fig. 5D; Pb0.01)
promoter activity, giving further support for co-operativity between
AP1 and NFAT.
3.6. CXCL8 enhances Ishikawa FPS cell proliferation in vitro
CXCL8 has recently been shown to enhance the proliferation and
migration of squamous carcinoma cells [34]. We treated Ishikawa FPS
cells in vitro with CXCL8 peptide and found signiﬁcantly augmented
cellular proliferation compared with vehicle treated cells (Fig. 5E;
Pb0.01). Co-treatment of cells with CXCL8 and the CXCR2 antagonistSB225002 abolished the CXCL8-induced increase in cell proliferation
at all time points investigated (Fig. 5E; Pb0.01).
3.7. CXCL8 expression in endometrial adenocarcinoma and
normal endometrium
We next explored the expression of CXCL8 in endometrial
adenocarcinoma and normal endometrial tissues and its potential
regulation by PGF2α via the FP receptor. CXCL8 (Fig. 6A) mRNA
expression was signiﬁcantly up-regulated in endometrial adenocar-
cinoma irrespective of grade or stage of cancer compared with normal
endometrium (Pb0.001). CXCL8 immunoreactivity in endometrial
Fig. 5. RCAN1-4 is a negative regulator of CXCL8 mRNA in FPS cells. (A) Ishikawa FPS cells were infected with 1 molecule of infection (MOI) per cell of scrambled lentivirus control or
RCAN1-4 ShRNA lentivirus (1 or 2 MOI) as described in the Methods. Immunoblotting was performed using standard techniques using a speciﬁc RCAN antibody.β-Actin was used in
parallel as a loading control. We conﬁrmed that RCAN1-4 was a negative regulator of CXCL8 expression using a lentiviral ShRNA targeted against RCAN1-4. Infection of FPS cells with
the RCAN1-4 lentiviral ShRNA enhanced the PGF2α-mediated induction of CXCL8 mRNA (B) and protein (C) expression in FPS cells treated with 1 nM PGF2α for 8 h compared with
control scrambled lentivirus. (D) Ishikawa FPS cells were transiently transfected with the pAP1-luc or pNFAT-luc cDNA containing the AP1 or NFAT cis-acting enhancer elements
respectively and infected with either scrambled control adenovirus or RCAN1-4 adenovirus for 24 h. Cells were then treated with vehicle or 100 nM PGF2α for 8 h and AP1 and NFAT
luciferase activity was measured by luciferase reporter assay. (E) Cell proliferation was determined in Ishikawa FPS cells treated with vehicle or recombinant CXCL8 for 24, 48 and
72 h in the absence/presence of the CXCR2 antagonist SB225002. (b is signiﬁcantly different from a and c is signiﬁcantly different from a and b; Pb0.01). Data are represented as
mean±SEM.
1924 K.J. Sales et al. / Biochimica et Biophysica Acta 1793 (2009) 1917–1928adenocarcinomas was observed in the glandular epithelium (G; as
indicated by the brown staining) with some diffuse stromal (S),
staining irrespective of grade/stage of endometrial adenocarcinoma
(Fig. 6B).
PGF2α stimulation of endometrial adenocarcinoma explants
resulted in a signiﬁcant increase in the expression of CXCL8 mRNA
(Fig. 6C) and secretion of CXCL8 protein (Fig. 6D), which was inhi-
bited by co-treatment of tissue explants with the speciﬁc FP receptor
antagonist AL8810 (Pb0.001). Furthermore, infection of endometrial
adenocarcinoma explants (Fig. 6E; Pb0.001) using RCAN1-4
adenovirus signiﬁcantly reduced the PGF2α-FP receptor induction
of CXCL8 mRNA expression compared to tissue infected with the
scrambled control virus similar to our in vitro data using Ishikawa
FPS cells.3.8. CXCL8 enhances Ishikawa FPS cell proliferation in nude mice in vivo
To explore whether CXCL8 induced by FP receptor signalling
could alter tumour growth in vivo we injected wild type Ishikawa
(WT) cells or FPS cells subcutaneously into the dorsal ﬂanks of nude
mice. Mice were then regularly injected with control IgG (WT and
FPS xenografts) or CXCL8 antibody (FPS xenografts). Tumours
formed from FPS cells expressed signiﬁcantly higher CXCL8 mRNA
as compared to WT tumours indicating that there was sufﬁcient
endogenous PGF2α in nude mice to induce CXCL8 expression in vivo
via the FP receptor similar to our observations in these cell lines vitro
(data not shown). Immunohistochemical staining showed a signif-
icant reduction in the BrdU incorporation in the epithelial compart-
ment of the mouse tumours in the animals engrafted with FPS
Fig. 6. CXCL8 expression and localization in endometrial tissues. (A) Relative mRNA expression of CXCL8 in endometrial adenocarcinoma (n=30; 10 of each poorly moderately
and well differentiated adenocarcinoma) and normal endometrium (n=30; 10 of each proliferative, early secretory and mid secretory endometrium) as determined by
quantitative RT-PCR analysis. (B) Immunolocalisation of CXCL8 in an example of Well differentiated endometrial adenocarcinoma as determined by immunohistochemistry
showing positive immunoreactivity (brown staining) in the glandular (G) and stromal (S) compartment. (C) CXCL8 mRNA and (D) protein expression in endometrial
adenocarcinoma explants (n=3) following treatment of tissue for 24 h with vehicle, 100 nM PGF2α or 100 nM PGF2α and AL8810. (E) Infection of endometrial adenocarcinoma
explants with scrambled (Scr) or RCAN1-4 adenovirus prior to stimulation with vehicle or 100 nM PGF2α for 24 h (b is signiﬁcantly different from a; Pb0.001). Data are
represented as mean±SEM. Scale bar=50 μm.
1925K.J. Sales et al. / Biochimica et Biophysica Acta 1793 (2009) 1917–1928tumour and treated with a CXCL8 neutralising antibody compared
with FPS IgG controls (Fig. 7A; Pb0.001). In addition, we found that
the administration of the CXCL8 neutralising antibody to FPS
xenografts had reduced the amount of cytokeratin 18 positive
immunoreactivity (as indicated by the brown staining) thereby
conﬁrming a reduction in the epithelial cell component of the
xenograft tumours (Fig. 7B and C, Pb0.001). However, we observed
no signiﬁcant reduction in tumour size or volume between the
various treatment groups during the 4 weeks of neutralising antibody
administration, but rather a gross inﬁltration of other cell types(stromal, vascular, immune cells as indicated by the blue haemato-
xylin counterstain) to maintain tumour volume as shown in the
representative image in Fig. 7B.
4. Discussion
Inﬂammation and infection are estimated to contribute to 25% of all
cancer cases world wide [2, 35]. Here we demonstrate that PGF2α-FP
receptor signalling can promote the expression of a potent chemokine
with known tumourigenic and angiogenic properties [17–19].
Fig. 7. CXCL8 enhances proliferation of Ishikawa FPS cells in vivo. (A, B, C) The effects of
CXCL8 neutralising antibody on epithelial cell proliferation in vivo. The CD1-Foxn1nu
mice were engrafted with Ishikawa FPS cells and treated with CXCL8 neutralising
antibody (n=10) or IgG control (n=10). The incorporation of BrdU (A) in the
epithelial compartment and number of epithelial cells as determined by cytokeratin 18
positive immunoreactivity (B) per tissue section were determined by immunohisto-
chemistry (brown staining) and quantiﬁed (C) by standard stereology techniques. (b is
signiﬁcantly different from a; c is signiﬁcantly different from a, b and d, d is signiﬁcantly
different from a, b and c; Pb0.001). Data are represented as mean±SEM. Scale
bar=50 μm.
Fig. 8. Summary. A schematic summary of our ﬁndings which includes the points of
inhibition of the various inhibitors outlined in Table 1 on the signalling cascade. PGF2α-
FP receptor activation in endometrial adenocarcinoma cells promotes the induction of
RCAN1-4 and CXCL8 via the Gq-PLC-PKC–calcium–calcineurin–NFAT cascade. The
expression of RCAN1-4 and CXCL8 are reciprocal and RCAN1-4 expression precedes
CXCL8 expression by 4–8 h. We found that RCAN1-4 acts as a negative regulator of the
calcineurin pathway to prevent over induction of CXCL8, such that when levels of
RCAN1-4 are high, CXCL8 levels are suppressed. When RCAN1-4 levels wane over time,
CXCL8 expression is induced to maximal to promote tumour cell proliferation via the
CXCR2 receptor on epithelial cells.
1926 K.J. Sales et al. / Biochimica et Biophysica Acta 1793 (2009) 1917–1928Chemokines have emerged as important regulators of tumour
function in colorectal carcinomas [15], melanomas, pancreatic, head
and neck and lung carcinomas [2], and are known to promote angio-
genesis and proliferation of endometrial stromal cells [14,36–38].
Moreover we have recently shown that chemokines regulated by
the FP receptor can also induce neutrophil chemotaxis in endome-
trial adenocarcinomas [16]. In the present study we have demon-
strated that PGF2α promotes the synthesis and release of CXCL8 in a
time-dependent manner via the protein kinase C–calcium–calci-
neurin–NFAT signalling pathway. Using luciferase reporter gene
analysis and site directed mutations of the AP1 or NFAT [21]
binding site on the CXCL8 promoter we determined that both AP1
and NFAT were essential for gene activation by PGF2α and that this
was independent of NFκB. Moreover we determined that both AP1-
and NFAT cis-acting enhancer elements were regulated by the same
protein kinase C–calcium–calcineurin–NFAT pathway which regu-
lates CXCL8 activation. NFAT and AP1 are known to co-operate and
mutually stabilise each others interaction with the DNA binding
domain to allow full gene transactivation to occur, and thisinteraction is critical for transcription of cytokines such as
interleukin-2 [39]. Furthermore, NFAT has been shown to complex
with the two AP1 subunits, cJun and cFos via direct protein-protein
interactions to co-ordinate promoter activity [28–30]. We found
that disruption of the AP1 complex with dn c-Jun or transretinoic
acid, abolished not only the ability of PGF2α to mediate transactiva-
tion of the AP1 cis-acting enhancer element, but also abolished the
PGF2α -mediated transactivation of the NFAT luciferase reporter
gene as well as the −162 and full length −1400 CXCL8 luciferase
reporter gene. These data give further support to the co-ordinated
regulation of CXCL8 transcription by a protein complex comprising
of the AP1 proteins and NFAT.
NFAT activation by calcineurin, which mediates its dephos-
phorylation and translocation to the nucleus is known to be
regulated by the regulator of calcinerin (RCAN) [32]. RCAN1-4 is
known to bind to calcineurin and previous studies have shown
that overexpression of this protein results in an inhibition of
calcineurin activation of NFAT [27, 33]. We showed that RCAN1-4
was regulated by PGF2α in a reciprocal time-dependent manner to
that of CXCL8, with a peak that preceded CXCL8 by 8 h, via the
calcium–calcineurin–NFAT pathway. This is in agreement with
other published observations that show that expression of this
isoform is induced by NFAT [27] and can negatively regulate
prokineticin-prokineticin receptor 1 signaling to CXCL8 in endo-
metrial epithelial cells [25]. Moreover adenovirus and lentivirus
infection studies showed that RCAN1-4 is a negative regulator of
PGF2α-FP receptor mediated induction of CXCL8 by inhibiting the
PGF2α- mediated activation of the AP1 and NFAT cis-acting
enhancer elements, similar to our observations for the dn c-Jun
and transretinoic acid, giving further support for the co-operativity
of NFAT and AP1 in mediating the full transcriptional activation of
CXCL8.
1927K.J. Sales et al. / Biochimica et Biophysica Acta 1793 (2009) 1917–1928We investigated the effect of CXCL8 on cellular proliferation
since humanised CXCL8 antibody has recently been shown to
inhibit tumour growth in vivo [40]. We found that CXCL8 could
enhance epithelial cell proliferation via interaction with the CXCR2
in vitro.
To determine whether PGF2α-FP receptor signaling regulates
CXCL8 in endometrial adenocarcinomas, we determined the expres-
sion pattern and localization of CXCL8 in endometrial adenocarcinoma
tissue. We found that CXCL8 mRNA expression was elevated in
endometrial adenocarcinomas irrespective of grade or stage and loca-
lized to the neoplastic glandular epithelial compartment with some
diffuse stromal staining—similar to expression reported for this
chemokine in normal endometrial glandular epithelium [36]. Further-
morewehave shown that CXCL8 immunolocalised to the same cellular
compartment in endometrial adenocarcinomas as the FP receptor and
CXCR2 (the receptor for CXCL8) [16] and that CXCL8 expression and
release is regulated in endometrial carcinoma explants ex vivo by
PGF2α via the FP receptor. Moreover we have shown that CXCL8
expression in endometrial adenocarcinoma explants is negatively
regulated by RCAN1-4 since infection of endometrial adenocarcinoma
explants with RCAN1-4 adenovirus abolished the PGF2α-FP receptor-
mediated induction of CXCL8. These data suggest that the molecular
mechanism thatwe have elucidated for the regulation of CXCL8 via the
RCAN1-4 pathway in vitro can potentially regulate CXCL8 in endome-
trial adenocarcinomas. Although little is known of the role of CXCL8 in
endometrial cancer, dysregulated CXCL8 and CXCR2 expression has
recently been proposed to play a role in other endometrial disorders
such as endometriosis [14, 38]. Furthermore, CXCL8 has recently been
shown to enhance the proliferation and migration of squamous
carcinoma cells [34] and its elevated secretion in esophageal
squamous cell carcinomas has been related to lymph node and distant
metastases [41].
Finally we investigated the impact of CXCL8 expression on tumour
development in vivo by engrafting nude mice with wild type Ishikawa
cells and FPS Ishikawa cells. We found that CXCL8 expression was
signiﬁcantly elevated in FPS xenograft tumours compared with wild
type tumours indicating that FP receptor was being activated by
endogenous PGF2α in vivo similar to our observations using FPS cells
and administering exogenous PGF2α in vitro. We further conﬁrmed
that CXCL8 played a role in epithelial cell function in vivo, as Ishikawa
FPS cell tumour xenografts in nude mice treated with a CXCL8
neutralising antibody displayed reduced neoplastic epithelial cell
proliferation characterised by reduced BrdU incorporation and
reduced cytokeratin 18 immunoreactivity, compared to IgG treated
controls. Further studies are currently underway in our laboratory to
determine whether alterations in cell type and density within a
tumour effects tumour outcome.
Taken together, our data (as summarised in Fig. 8) show that
PGF2α-FP receptor activation in endometrial adenocarcinoma cells
promotes the activation of RCAN1-4 and CXCL8 via the Gq-PLC-PKC–
calcium–calcineurin–NFAT. The activation of RCAN1-4 is reciprocal to
CXCL8, such that at the peak of RCAN1-4 expression, CXCL8 expression
is minimal and vice versa. As RCAN1-4 expression reduces over time,
the expression of CXCL8 increases to promote tumour cell prolifera-
tion. Furthermore, we conﬁrmed that RCAN1-4 is a potent negative
regulator of CXCL8 in vitro and ex vivo in endometrial adenocarcinomas
explants and that the regulation of transcriptional activation of CXCL8
by PGF2α occurs via the co-operativity between AP1 and NFAT DNA
binding elements. To our knowledge this represents the ﬁrst report
mapping the molecular and cellular regulation of CXCL8 by prosta-
noids and its potential involvement in endometrial cancers.
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